Deep Track Capital

Deep Track Capital is a Greenwich, Connecticut-based investment firm focused exclusively on the life sciences industry. They develop long-term partnerships with management teams of leading innovative public and pre-IPO biotechnology companies. In addition to capital, they seek to invest their time and expertise, while leveraging their network for the benefit of their partners. They aim to lead transactions while building large syndicates and also invest in rounds led by other qualified investors.

In 2024, Deep Track Capital participated in six funding rounds across various stages, including Seed, PIPE, and Series A-D. Notable additions to its portfolio include enGene, Jade Biosciences, TORL BioTherapeutics, and MBX Biosciences. The firm’s largest single investment was a $555 million PIPE funding in Bicycle Therapeutics. Their investment approach is fundamentally driven, aiming to capitalize on the varied outcomes within biotech development. They focus on therapeutic areas such as oncology, infectious diseases, neurology, immunology, ophthalmology, hepatology, dermatology, and cardiology, and technological focuses including antibodies, small molecules, cell and gene therapies, immunotherapies, peptides, antibody conjugates, and ophthalmic devices.